Camden National Bank Sells 1,353 Shares of Johnson & Johnson (NYSE:JNJ)

Camden National Bank lessened its holdings in Johnson & Johnson (NYSE:JNJ) by 1.8% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 75,876 shares of the company’s stock after selling 1,353 shares during the quarter. Johnson & Johnson accounts for 1.8% of Camden National Bank’s investment portfolio, making the stock its 21st largest position. Camden National Bank’s holdings in Johnson & Johnson were worth $12,296,000 as of its most recent SEC filing.

A number of other institutional investors have also recently bought and sold shares of JNJ. China Universal Asset Management Co. Ltd. bought a new position in shares of Johnson & Johnson during the 1st quarter worth $765,000. Beaird Harris Wealth Management LLC grew its stake in shares of Johnson & Johnson by 19.1% during the 1st quarter. Beaird Harris Wealth Management LLC now owns 2,778 shares of the company’s stock worth $439,000 after acquiring an additional 446 shares during the period. Mount Yale Investment Advisors LLC grew its stake in shares of Johnson & Johnson by 4.9% during the 1st quarter. Mount Yale Investment Advisors LLC now owns 22,051 shares of the company’s stock worth $3,488,000 after acquiring an additional 1,033 shares during the period. QVR LLC bought a new position in shares of Johnson & Johnson during the 1st quarter worth $478,000. Finally, Lavaca Capital LLC grew its stake in shares of Johnson & Johnson by 1.3% during the 1st quarter. Lavaca Capital LLC now owns 6,418 shares of the company’s stock worth $1,015,000 after acquiring an additional 85 shares during the period. Institutional investors own 69.55% of the company’s stock.

Johnson & Johnson Stock Performance

Shares of NYSE JNJ opened at $155.14 on Friday. The stock has a market cap of $373.52 billion, a price-to-earnings ratio of 22.45, a P/E/G ratio of 2.76 and a beta of 0.53. The company has a current ratio of 1.03, a quick ratio of 0.79 and a debt-to-equity ratio of 0.45. Johnson & Johnson has a 1-year low of $143.13 and a 1-year high of $168.85. The stock’s 50-day moving average is $160.21 and its 200 day moving average is $156.21.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings data on Tuesday, October 15th. The company reported $2.42 earnings per share for the quarter, beating analysts’ consensus estimates of $2.21 by $0.21. The company had revenue of $22.47 billion for the quarter, compared to analysts’ expectations of $22.17 billion. Johnson & Johnson had a return on equity of 35.45% and a net margin of 19.14%. Johnson & Johnson’s revenue for the quarter was up 5.2% compared to the same quarter last year. During the same period last year, the firm posted $2.66 EPS. On average, sell-side analysts anticipate that Johnson & Johnson will post 9.93 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, December 10th. Shareholders of record on Tuesday, November 26th will be paid a $1.24 dividend. The ex-dividend date of this dividend is Tuesday, November 26th. This represents a $4.96 dividend on an annualized basis and a yield of 3.20%. Johnson & Johnson’s dividend payout ratio (DPR) is currently 71.78%.

Insiders Place Their Bets

In other news, VP Robert J. Decker sold 5,635 shares of the business’s stock in a transaction that occurred on Friday, August 30th. The stock was sold at an average price of $165.06, for a total transaction of $930,113.10. Following the transaction, the vice president now directly owns 18,973 shares of the company’s stock, valued at approximately $3,131,683.38. The trade was a 22.90 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 0.16% of the company’s stock.

Analyst Ratings Changes

Several research analysts have recently weighed in on JNJ shares. Citigroup increased their price target on Johnson & Johnson from $180.00 to $185.00 and gave the stock a “buy” rating in a research note on Wednesday, October 16th. Wolfe Research assumed coverage on Johnson & Johnson in a research note on Friday, November 15th. They issued an “outperform” rating and a $190.00 target price for the company. Cantor Fitzgerald restated an “overweight” rating and issued a $215.00 target price on shares of Johnson & Johnson in a research note on Wednesday, October 16th. Wells Fargo & Company raised their target price on Johnson & Johnson from $163.00 to $166.00 and gave the stock an “equal weight” rating in a research note on Wednesday, October 16th. Finally, Morgan Stanley raised their target price on Johnson & Johnson from $169.00 to $175.00 and gave the stock an “equal weight” rating in a research note on Wednesday, October 16th. Seven equities research analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $175.94.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.